|
Ranpirnase also known
as onconase is a promising new chemotherapy
drug currently in clinical trials as a treatment against the
mesothelioma. It is a ribonuclease enzyme meaning that it
catalyzes the breakdown of RNA.
The drug is made by the Alfacell Corporation and currently
trademarked as Onconase.
Origins of Ranpirnase
Ranpirnase is a specialized enzyme found originally in frogs
that speeds up the an enzyme that specializes in the break
down of RNA which in turn can destroy a cell or stop it from
dividing.
It is now being investigated as a possible treatment to certain
cancers, including mesothelioma.
When a cancer cell divides it uses RNA to help form a new
copy of itself. Ranpirnase works by breaking down RNA which
is used to code for a cell’s DNA thus killing or disabling
a cell.
Availability
The drug is currently in the final stages of clinical trials
and has yet to be approved by the FDA.
Clinical Trial: ONCONASE
Plus Doxorubicin Versus Doxorubicin Alone For Patients With
Malignant Pleural or Peritoneal Mesothelioma Who Have Had
No More Than One Prior Chemotherapy Regimen
Ranpirnase
Effective in Malignant Mesothelioma
Mild
hyperthermia predisposes tumor cells to undergo apoptosis
upon treatment with onconase.
Human
mesothelioma cells exhibit tumor cell–specific differences
in phosphatidylinositol 3-kinase/AKT activity that predict
the efficacy of Onconase
Chemical Properties of Ranpirnase
Antitumor
efficacy of the cytotoxic RNase, ranpirnase, on A549 human
lung cancer xenografts of nude mice.
About Us
Ranprinase.org provides information about the cancer drug
Ranprinase.We do not buy or sell ranpirnase and we are in
no way affiliated or associated with Alfacell Corporatation
or any other pharmaceutical company.
Disclaimer
This site was not prepared by medical professionals. Consult
a doctor for specific questions about treatment..
|